4//SEC Filing
DiRocco Derek 4
Accession 0001209191-22-057421
CIK 0001781174other
Filed
Nov 15, 7:00 PM ET
Accepted
Nov 16, 9:05 PM ET
Size
6.1 KB
Accession
0001209191-22-057421
Insider Transaction Report
Form 4
DiRocco Derek
Director
Transactions
- Award
Stock Option (Right to Buy)
2022-11-14+35,235→ 35,235 totalExercise: $12.50Exp: 2032-11-13→ Common Stock (35,235 underlying)
Footnotes (2)
- [F1]The shares subject to the option shall vest in 36 equal monthly installments starting on October 12, 2022 ("Vesting Commencement Date"), such that all shares are fully vested on the third anniversary of the Vesting Commencement Date, in each case subject to the Reporting Person's continuous service through each such vesting date.
- [F2]Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund II. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.
Documents
Issuer
Acrivon Therapeutics, Inc.
CIK 0001781174
Entity typeother
Related Parties
1- filerCIK 0001792061
Filing Metadata
- Form type
- 4
- Filed
- Nov 15, 7:00 PM ET
- Accepted
- Nov 16, 9:05 PM ET
- Size
- 6.1 KB